Previous reports have documented that, among its diverse mechanisms of activity, as a pan-HDAC inhibitor panobinostat transcriptionally perturbs large numbers of gene-expressions beyond what would be regulated by menin-MLL1 in AML cells, including repression of pro-growth and pro-survival gene-expressions [49]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.